CN107102143B - 嗜吞噬细胞无形体蛋白aph1384的应用 - Google Patents

嗜吞噬细胞无形体蛋白aph1384的应用 Download PDF

Info

Publication number
CN107102143B
CN107102143B CN201710149621.XA CN201710149621A CN107102143B CN 107102143 B CN107102143 B CN 107102143B CN 201710149621 A CN201710149621 A CN 201710149621A CN 107102143 B CN107102143 B CN 107102143B
Authority
CN
China
Prior art keywords
aph1384
albumin
anaplasma phagocytophila
serum
phagocytophila
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710149621.XA
Other languages
English (en)
Other versions
CN107102143A (zh
Inventor
牛华
贺美玲
吴淑燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to CN201710149621.XA priority Critical patent/CN107102143B/zh
Priority to PCT/CN2017/087912 priority patent/WO2018166079A1/zh
Priority to US16/321,824 priority patent/US10598660B2/en
Publication of CN107102143A publication Critical patent/CN107102143A/zh
Application granted granted Critical
Publication of CN107102143B publication Critical patent/CN107102143B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/29—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Richettsiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及嗜吞噬细胞无形体蛋白APH1384作为粒细胞无形体病诊断抗原的应用，该蛋白可弥补现有粒细胞无形体病诊断抗原P44漏检的缺陷，提高了粒细胞无形体病检测的灵敏度，有利于临床上快速精准地诊断粒细胞无形体病的发生。

Description

嗜吞噬细胞无形体蛋白APH1384的应用
技术领域
本发明涉及免疫学领域，尤其涉及一种嗜吞噬细胞无形体蛋白APH1384的应用。
背景技术
嗜吞噬细胞无形体是一种专性细胞内寄生的以蜱虫为传播媒介的革兰氏阴性菌，能导致粒细胞无形体病，如人粒细胞无形体病和犬粒细胞无形体病的发生。美国CDC的数据显示，从2000年到2012年人粒细胞无形体病的感染例数由348例增至2389例，呈快速增长的趋势。此外，粒细胞无形体病在澳大利亚、欧洲多国、日本及韩国的人群和家畜中发生局部流行。在国内，由中国疾控中心组织的血清流行病学调查表明，我国的农业从业者中粒细胞无形体病的血清阳性率高达13.9％。与欧美粒细胞无形体病患者相比，我国无形体病患者病情更为严重，死亡率可高达8.1％。我国的病人会发展成其他严重的症状，如其中41.2％会发展成多器官衰竭。另外，据中国疾控中心调查，在犬和羊的嗜吞噬细胞无形体检测中，血清阳性率分别高达10.05％和3.82％。目前，粒细胞无形体病已在世界范围内流行，成为重要的公共卫生问题。因此加强粒细胞无形体病诊断方法的优化，对医学、公共卫生及畜牧业领域具有十分重要的现实意义。
目前，粒细胞无形体病血清学诊断方法是以嗜吞噬细胞无形体来源的特异性种属蛋白为诊断抗原，检测被感染对象血清中抗该病原菌的特异性抗体，从而判断受试者是否感染嗜吞噬细胞无形体。血清学诊断方法主要包括间接免疫荧光技术(Indirectfluorescent antibody assays,IFA)，免疫印记技术(Western Blotting和Dot Blotting,WB和DB)及酶联免疫吸附实验(ELISA)。对于人或动物大批量血清样本的检测主要使用ELISA和DB方法。
IFA方法是使用嗜吞噬细胞无形体感染的细胞制备成抗原片，对临床血清标本中抗嗜吞噬细胞无形体的特异性抗体进行检测。通过孵育标记有荧光素的二抗，在荧光显微镜下观察抗原片上的荧光强度判断血清是否为阳性。该技术是目前临床上用于检测粒细胞无形体病感染的金标准，但是操作复杂，判断结果主观，且抗原片的价格昂贵，因此不适合临床上大批量血清样本的检测。而WB，DB和ELISA检测方法以嗜吞噬细胞无形体特异性重组蛋白或蛋白抗原表位多肽为诊断抗原，检测人或动物血清样本中是否存在抗嗜吞噬细胞无形体的特异性抗体。其中，ELISA方法简单，可自动化，可以用于大量临床样本的检测。但目前，这三种血清学检测方法所使用的诊断抗原均为嗜吞噬细胞无形体外膜蛋白P44，而以P44作为单一诊断抗原的检测方法存在漏检的缺陷，其检测灵敏度为80-90％。总之，IFA法检测成本高，需要价格昂贵的抗原片，且判定结果主观，操作时间相对较长，不适合大量临床样本的检测；而WB，DB和ELISA法虽然操作简单，成本低，但目前他们均以P44作为单一诊断抗原，存在漏检的缺陷，检测灵敏度有待提高。
发明内容
为解决上述检测方法的不足，本发明的目的是提供一种嗜吞噬细胞无形体蛋白APH1384的应用，该蛋白抗原性较强，能弥补P44漏检的缺陷，可提高粒细胞无形体病检测的灵敏度，从而有利于临床上快速精准地诊断粒细胞无形体病的发生。
本发明提供了一种检测嗜吞噬细胞无形体蛋白APH1384的抗体在制备粒细胞无形体病诊断试剂中的应用。
进一步地，嗜吞噬细胞无形体蛋白APH1384的氨基酸序列如SEQ ID No.1所示。
进一步地，嗜吞噬细胞无形体蛋白APH1384的抗原表位的氨基酸序列如SEQ IDNo.2所示。
借由上述方案，本发明至少具有以下优点：
本发明提供了一种粒细胞无形体病血清学诊断抗原APH1384，该蛋白可弥补现有粒细胞无形体病诊断抗原P44漏检的缺陷，提高了粒细胞无形体病检测的灵敏度，有利于临床上快速精准地诊断粒细胞无形体病的发生。
上述说明仅是本发明技术方案的概述，为了能够更清楚了解本发明的技术手段，并可依照说明书的内容予以实施，以下以本发明的较佳实施例并配合附图详细说明如后。
附图说明
图1是APH1384蛋白的SDS-PAGE电泳检测结果；
图2图示了APH1384抗原性的WB技术检测结果；
图3图示了APH1384多肽抗原性的DB技术验证结果。
具体实施方式
下面结合附图和实施例，对本发明的具体实施方式作进一步详细描述。以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例1APH1384蛋白(嗜吞噬细胞无形体种属特异性蛋白)的制备
利用生物信息学技术，以嗜吞噬细胞无形体基因组编码的610个未知功能蛋白为靶标，筛选出嗜吞噬细胞无形体种特异性蛋白。对其中一些蛋白(包括APH1384)进行了克隆表达和抗原性鉴定。研究结果发现APH1384具有强的抗原性。以下为APH1384详细的克隆表达和抗原性鉴定步骤。根据Gene Bank中aph1384基因序列设计含有限制性核酸内切酶位点的特异性引物：aph1384-F-TCCGAATTCATGTTTGATATATTTAATGATGCTG；aph1384-R-GCACTCGAGTTATTCGGACGCAGAGGCT。以嗜吞噬细胞无形体的全基因组DNA为模板，PCR扩增aph1384基因的DNA片段。将扩增的目的基因DNA片段和原核表达载体pET28a(+)分别用限制性核酸内切酶双酶切，并使用T4DNA连接酶进行连接。连接产物转化至克隆宿主菌E.coliTOP10中，提取质粒进行测序，将阳性质粒转化至表达宿主菌E.coli BL21(DE3)中进行蛋白表达。37℃条件下培养含重组质粒的E.coli BL21(DE3)，加入IPTG诱导APH1384蛋白的表达，诱导3.5h后，离心收集菌体，变性裂解处理后通过SDS-PAGE电泳检测APH1384蛋白的表达水平，结果如图1所示。图1显示在21.5kDa大小处出现目标蛋白条带，而未加IPTG对照组，无目标蛋白条带。采用镍柱亲和层析的方法纯化APH1384蛋白，其氨基酸序列如SEQ IDNo.1所示。
以纯化的嗜吞噬细胞无形体种属特异性蛋白APH1384为抗原，使用6份嗜吞噬细胞无形体阳性血清通过WB技术检测APH1384的抗原性。首先将纯化的重组APH1384蛋白上样于SDA-PAGE胶，蛋白转至硝酸纤维素膜，将膜切为条状，封闭30min，与一抗阳性血清(1:2000)进行孵育，PBS洗涤3次，与二抗(HRP标记的羊抗人IgG，1:5000)进行孵育，PBS洗涤4次，显影。结果见图2，其中图2中的1-6分别代表嗜吞噬细胞无形体阳性人血清，APH1384即为嗜吞噬细胞无形体种属特异性蛋白。结果显示6份阳性血清均能与APH1384反应。APH1384蛋白与嗜吞噬细胞无形体阳性血清呈现较强阳性反应，说明APH1384具有较强的抗原性。
实施例2APH1384多肽的制备
利用生物信息学方法预测获得APH1384的抗原表位，其氨基酸序列如SEQ ID No.2所示。化学合成APH1384抗原表位多肽，利用DB技术对APH1384多肽的抗原性进行验证，具体操作如下：
将APH1384多肽抗原稀释液(浓度分别为1μg/μl、0.1μg/μl、0.01μg/μl)加至硝酸纤维素膜，37℃干燥20-30min，封闭30min，一抗即人阳性血清(1:2000)孵育1h，二抗孵育1h(1:5000)，显影。结果见图3，图3中的N代表阴性血清，P1-P3各代表一份嗜吞噬细胞无形体阳性血清，结果显示，阴性血清不与APH1384反应，而3份阳性血清均与APH1384多肽结合，证明APH1384多肽具有抗原性。
实施例3APH1384多肽的应用
以合成的APH1384多肽为包被抗原，使用ELISA法检测人血清中特异性抗APH1384抗体，具体操作步骤如下：
(1)包板：将实施例2合成的APH1384多肽用PBS稀释至20μg/ml，4℃过夜或室温下2h包板(96孔板，每孔50μl)；
(2)封闭：使用PBS清洗96孔板三次，加入小牛血清白蛋白(浓度为1％)的封闭液，每孔200μl，37℃，2h；
(3)一抗孵育：使用封闭液按1:1000的比例稀释待检血清，每孔加入稀释液100μl，37℃孵育1h；
(4)二抗孵育：使用PBS清洗四次(每孔200μl)，加入二抗(HRP标记的羊抗人IgG，1:5000稀释)，37℃孵育1h；
(5)显色：使用PBS清洗3-5次，加入配制好的显色液，每孔100μl，37℃避光10-15min后即加入终止液(浓度为1M的稀盐酸)，每孔100μl，以终止反应。在终止反应后的15分钟内，在450nm的波长处测定各孔溶液的吸光值；
(6)结果判定：计算Cutoff值(Cutoff值＝阴性对照的平均值+3*标准方差)，然后将检测孔中的吸光值与Cutoff值比较。当检测孔中吸光值大于Cutoff值时，表示血清中抗嗜吞噬细胞无形体抗体阳性；当检测孔中吸光值小于Cutoff值时，表示血清中抗嗜吞噬细胞无形体抗体阴性。
实施例4APH1384多肽的应用
以合成的APH1384多肽为抗原，使用DB法检测人血清中特异性抗APH1384抗体，具体操作步骤如下：
(1)点样：PBS(0.01M，PH 7.4)稀释APH1384多肽抗原至适宜的浓度(分别为1μg/μl、0.1μg/μl、0.01μg/μl)，使用移液器将1μl稀释液加至硝酸纤维素膜，置37℃温箱中干燥20-30min；
(2)封闭：加5ml封闭液(5％脱脂奶粉)于温育盒中，常温封闭30min；
(3)一抗孵育：弃封闭液，加封闭液稀释的人血清标本(1:2000)，室温孵育1h，用PBS震洗3次，每次10min；
(4)二抗孵育：加入封闭液稀释的HRP-羊抗人IgG二抗(1:5000)，室温孵育1h后用PBS震洗3次，每次10min；
(5)显影：ECL化学发光法显影，观察1μg/μl浓度的斑点是否显色，以此来判断血清抗嗜吞噬细胞无形体抗体阴阳性。阴性对照血清在膜片上不出现有颜色的斑点。待检血清如出现肉眼可见的斑点，则为抗嗜吞噬细胞无形体抗体阳性；待检血清如不出现肉眼可见的斑点，则为抗嗜吞噬细胞无形体抗体阴性。
本发明的APH1384蛋白或合成的多肽抗原作为粒细胞无形体病的诊断抗原，可通过多种血清学方法检测多物种血清中的特异性抗体以诊断此物种是否感染嗜吞噬细胞无形体。血清学方法包括ELISA、DB、WB，但不仅限于这三种方法，多物种血清包括人、狗、猫、马等。
以上所述仅是本发明的优选实施方式，并不用于限制本发明，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明技术原理的前提下，还可以做出若干改进和变型，这些改进和变型也应视为本发明的保护范围。
序列表
<110> 苏州大学
<120> 嗜吞噬细胞无形体蛋白APH1384的应用
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 160
<212> PRT
<213> 氨基酸序列
<400> 1
Met Phe Asp Ile Phe Asn Asp Ala Val Val Ala Ser Val Ser Thr
1 5 10 15
Ala Pro Thr Gly Thr His Leu Ser Phe Pro Gly Ala Cys Gly Asp
20 25 30
Phe Ser Leu Glu Asn Leu Pro Leu Ile Lys Ser His Ser Phe Glu
35 40 45
Tyr Asp Leu Val Thr Gly Tyr Glu Tyr Thr Val Leu Arg Phe Gly
50 55 60
Ser Glu Lys Gln Glu Asp Gln Asn Ser Ser Thr Tyr Met Leu Asp
65 70 75
Val Phe Phe Arg Arg Val Pro Asp Ser Asn Asp Ile Ser Leu Tyr
80 85 90
Ser Val Glu Trp Gly Glu Val Leu Ser Asn Ala Asn Thr Val His
95 100 105
Glu Lys Gln Ser Glu Asp Leu Arg Glu Lys Gly Arg Ser Met Ala
110 115 120
Met Cys Gly Leu Met Pro Asp Ser Thr Val Glu Gln Asp Gly Ala
125 130 135
Leu Val Leu Thr Ser Thr Gly His Ala Ala Lys Cys Lys Val Thr
140 145 150
Val Thr Leu Lys Val Ala Ser Ala Ser Glu
155 160
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 29
<212> PRT
<213> 氨基酸序列
<400> 2
Phe Gly Ser Glu Lys Gln Glu Asp Gln Asn Ser Ser Thr Tyr Met
1 5 10 15
Leu Asp Val Phe Phe Arg Arg Val Pro Asp Ser Asn Asp Ile
20 25

Claims (3)

1.检测嗜吞噬细胞无形体蛋白APH1384的抗体在制备粒细胞无形体病诊断试剂中的应用。
2.根据权利要求1所述的应用，其特征在于：所述嗜吞噬细胞无形体蛋白APH1384的氨基酸序列如SEQ ID No.1所示。
3.根据权利要求1所述的应用，其特征在于：所述嗜吞噬细胞无形体蛋白APH1384的抗原表位的氨基酸序列如SEQ ID No.2所示。
CN201710149621.XA 2017-03-14 2017-03-14 嗜吞噬细胞无形体蛋白aph1384的应用 Active CN107102143B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201710149621.XA CN107102143B (zh) 2017-03-14 2017-03-14 嗜吞噬细胞无形体蛋白aph1384的应用
PCT/CN2017/087912 WO2018166079A1 (zh) 2017-03-14 2017-06-12 嗜吞噬细胞无形体蛋白aph1384的应用
US16/321,824 US10598660B2 (en) 2017-03-14 2017-06-12 Application of anaplasma phagocytophilum protein APH1384

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710149621.XA CN107102143B (zh) 2017-03-14 2017-03-14 嗜吞噬细胞无形体蛋白aph1384的应用

Publications (2)

Publication Number Publication Date
CN107102143A CN107102143A (zh) 2017-08-29
CN107102143B true CN107102143B (zh) 2018-11-02

Family

ID=59675214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710149621.XA Active CN107102143B (zh) 2017-03-14 2017-03-14 嗜吞噬细胞无形体蛋白aph1384的应用

Country Status (3)

Country Link
US (1) US10598660B2 (zh)
CN (1) CN107102143B (zh)
WO (1) WO2018166079A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112538119A (zh) * 2020-12-14 2021-03-23 杭州亿米诺生物科技有限公司 一种犬嗜吞噬细胞无形体p44重组蛋白及其制备方法和应用
CN114163507B (zh) * 2021-11-29 2023-06-20 河套学院 粒细胞无形体病检测用重组抗原蛋白rP44-60及含有该抗原的试剂盒
CN114315995B (zh) * 2021-12-21 2023-06-20 河套学院 嗜吞噬细胞无形体重组蛋白抗原的制备方法及含有该重组蛋白抗原的试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286093A (zh) * 2011-07-27 2011-12-21 中国人民解放军军事医学科学院基础医学研究所 一种嗜吞噬细胞无形体抗原及含有该抗原的试剂盒
KR20130123961A (ko) * 2012-05-04 2013-11-13 베트올 (주) 아나플라즈마 파고사이토필리움 균주의 탐지용 조성물, 및 이를 포함하는 면역진단키트
CN104055911A (zh) * 2013-05-17 2014-09-24 山东东阿阿胶股份有限公司 复方阿胶浆在制备预防或治疗人粒细胞无形体病的药物中的应用
CN104293960A (zh) * 2014-10-16 2015-01-21 中华人民共和国北京出入境检验检疫局 一种用于同时检测嗜吞噬细胞无形体和查菲埃里克体的双重荧光pcr的检测试剂盒及引物和探针
WO2016118766A2 (en) * 2015-01-21 2016-07-28 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of tick-borne pathogens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283130B2 (en) 2009-02-27 2012-10-09 Medical Diagnostic Laboratories, Llc Protein fragments of virB10 and sero-detection of anaplasma phagocytophium
CN101498729A (zh) * 2009-03-09 2009-08-05 浙江理工大学 快速诊断人粒细胞无形体病的免疫层析试纸及其制备法
EP3102234B1 (en) * 2014-02-03 2021-07-28 Virginia Commonwealth University Aipa, ompa, and asp14 in vaccine compositions and diagnostic targets for anaplasma phagocytophilum infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286093A (zh) * 2011-07-27 2011-12-21 中国人民解放军军事医学科学院基础医学研究所 一种嗜吞噬细胞无形体抗原及含有该抗原的试剂盒
KR20130123961A (ko) * 2012-05-04 2013-11-13 베트올 (주) 아나플라즈마 파고사이토필리움 균주의 탐지용 조성물, 및 이를 포함하는 면역진단키트
CN104055911A (zh) * 2013-05-17 2014-09-24 山东东阿阿胶股份有限公司 复方阿胶浆在制备预防或治疗人粒细胞无形体病的药物中的应用
CN104293960A (zh) * 2014-10-16 2015-01-21 中华人民共和国北京出入境检验检疫局 一种用于同时检测嗜吞噬细胞无形体和查菲埃里克体的双重荧光pcr的检测试剂盒及引物和探针
WO2016118766A2 (en) * 2015-01-21 2016-07-28 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of tick-borne pathogens

Also Published As

Publication number Publication date
WO2018166079A1 (zh) 2018-09-20
CN107102143A (zh) 2017-08-29
US10598660B2 (en) 2020-03-24
US20190170747A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CN107102143B (zh) 嗜吞噬细胞无形体蛋白aph1384的应用
CN103172752A (zh) 牛肺炎支原体的诊断试剂及应用
CN105906714A (zh) 一种布鲁氏菌病特异性融合蛋白抗原的制备及应用
KR101805451B1 (ko) 아나플라즈마 파고사이토필리움 균주의 탐지용 조성물, 및 이를 포함하는 면역진단키트
CN110133284A (zh) 蛋白抗原及其编码基因和它们在鉴别猪肺炎支原体灭活疫苗抗体和自然感染抗体中的应用
Lin et al. Application of purified recombinant antigenic spike fragments to the diagnosis of avian infectious bronchitis virus infection
CN111551750B (zh) 猪星状病毒间接elisa检测试剂盒
CN105242043B (zh) 一种鉴别诊断口蹄疫病毒感染的多物种通用elisa试剂盒
CN109142746A (zh) 检测猪流行性腹泻病毒抗体的酶联免疫试剂盒
CN110261615B (zh) 囊型包虫病诊断试剂盒及其应用
CN110031621A (zh) 一种hiv新发感染检测试剂盒和制备方法
Crowther Enzyme linked immunosorbent assay (ELISA)
CN110964089B (zh) 一种肺炎支原体抗原
Teimouri et al. Assessment of an in-house enzyme-linked immunosorbent assay and IgG avidity test based on SAG1 and GRA7 proteins for discriminating between acute and chronic toxoplasmosis in humans
CN107860919A (zh) 检测猪圆环病毒2型IgM抗体ELISA的试剂盒及检测方法
CN107219365A (zh) 一种基于口蹄疫病毒3b表位蛋白的化学发光检测试剂盒
CN108956988B (zh) 一种羊口疮病毒抗体间接elisa检测试剂盒、检测方法及应用
WO2013178737A1 (en) Method for diagnosing and differentiating hiv-2 infections
CN110376388A (zh) 一种副猪嗜血杆菌抗体检测方法及其试剂盒
CN110221060A (zh) 一种用于早期诊断捻转血矛线虫感染的抗原及其应用
CN106478784B (zh) 用于检测抗人乳头瘤病毒抗体的抗原及相关免疫检测试剂盒
Yang et al. A novel double-antigen sandwich enzyme-linked immunosorbent assay for measurement of antibodies against rabies virus
CN101509002B (zh) 一种重组风疹病毒蛋白及其应用
CN110294796B (zh) 用于制备细粒棘球蚴病诊断试剂的多肽及其应用
CN113684189A (zh) 一株鸡新型圆圈病毒3型毒株及基于该病毒的检测体系

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant